| Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19 A Bonaventura, A Vecchié, L Dagna, K Martinod, DL Dixon, ... Nature Reviews Immunology 21 (5), 319-329, 2021 | 850 | 2021 |
| Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with … S Mazloomzadeh, S Khaleghparast, B Ghadrdoost, M Mousavizadeh, ... Jama 325 (16), 1620-1630, 2021 | 693 | 2021 |
| The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse E Mezzaroma, S Toldo, D Farkas, IM Seropian, BW Van Tassell, ... Proceedings of the National Academy of Sciences 108 (49), 19725-19730, 2011 | 653 | 2011 |
| Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease A Abbate, S Toldo, C Marchetti, J Kron, BW Van Tassell, CA Dinarello Circulation research 126 (9), 1260-1280, 2020 | 530 | 2020 |
| Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU … A Abbate, MC Kontos, JD Grizzard, GGL Biondi-Zoccai, BW Van Tassell, ... The American journal of cardiology 105 (10), 1371-1377. e1, 2010 | 435 | 2010 |
| Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University … A Abbate, BW Van Tassell, G Biondi-Zoccai, MC Kontos, JD Grizzard, ... The American journal of cardiology 111 (10), 1394-1400, 2013 | 410 | 2013 |
| Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis S Chatterjee, G Biondi-Zoccai, A Abbate, F D’Ascenzo, D Castagno, ... Bmj 346, 2013 | 408 | 2013 |
| Medication nonadherence: an unrecognized cardiovascular risk factor MA Munger, BW Van Tassell, J LaFleur Medscape general medicine 9 (3), 58, 2007 | 387 | 2007 |
| Anti-inflammatory strategies for ventricular remodeling following ST-segment elevation acute myocardial infarction IM Seropian, S Toldo, BW Van Tassell, A Abbate Journal of the American College of Cardiology 63 (16), 1593-1603, 2014 | 363 | 2014 |
| Targeting interleukin-1 in heart disease BW Van Tassell, S Toldo, E Mezzaroma, A Abbate Circulation 128 (17), 1910-1923, 2013 | 358 | 2013 |
| A novel pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury after ischemia–reperfusion in the mouse C Marchetti, J Chojnacki, S Toldo, E Mezzaroma, N Tranchida, SW Rose, ... Journal of cardiovascular pharmacology 63 (4), 316-322, 2014 | 270 | 2014 |
| Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study) BW Van Tassell, R Arena, G Biondi-Zoccai, JMN Canada, C Oddi, ... The American journal of cardiology 113 (2), 321-327, 2014 | 255 | 2014 |
| Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure BW Van Tassell, RA Arena, S Toldo, E Mezzaroma, T Azam, IM Seropian, ... PloS one 7 (3), e33438, 2012 | 232 | 2012 |
| Interleukin‐1 blockade inhibits the acute inflammatory response in patients with ST‐segment–elevation myocardial infarction A Abbate, CR Trankle, LF Buckley, MJ Lipinski, D Appleton, D Kadariya, ... Journal of the American Heart Association 9 (5), e014941, 2020 | 211 | 2020 |
| Inhibition of the NLRP3 inflammasome limits the inflammatory injury following myocardial ischemia–reperfusion in the mouse S Toldo, C Marchetti, AG Mauro, J Chojnacki, E Mezzaroma, S Carbone, ... International Journal of Cardiology 209, 215-220, 2016 | 206 | 2016 |
| Interleukin-1 blockade in recently decompensated systolic heart failure: results from REDHART (Recently Decompensated Heart Failure Anakinra Response Trial) BW Van Tassell, J Canada, S Carbone, C Trankle, L Buckley, ... Circulation: Heart Failure 10 (11), e004373, 2017 | 199 | 2017 |
| Metabolic gene remodeling and mitochondrial dysfunction in failing right ventricular hypertrophy secondary to pulmonary arterial hypertension J Gomez-Arroyo, S Mizuno, K Szczepanek, B Van Tassell, R Natarajan, ... Circulation: Heart Failure 6 (1), 136-144, 2013 | 199 | 2013 |
| Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review AH Talasaz, P Sadeghipour, H Kakavand, M Aghakouchakzadeh, ... Journal of the American College of Cardiology 77 (15), 1903-1921, 2021 | 190 | 2021 |
| Effect of canakinumab vs placebo on survival without invasive mechanical ventilation in patients hospitalized with severe COVID-19: a randomized clinical trial R Caricchio, A Abbate, I Gordeev, J Meng, PY Hsue, T Neogi, R Arduino, ... Jama 326 (3), 230-239, 2021 | 173 | 2021 |
| Pharmacologic inhibition of the NLRP3 inflammasome preserves cardiac function after ischemic and nonischemic injury in the mouse C Marchetti, S Toldo, J Chojnacki, E Mezzaroma, K Liu, FN Salloum, ... Journal of cardiovascular pharmacology 66 (1), 1-8, 2015 | 171 | 2015 |
Antonio AbbateProfessor of Cardiology, University of VirginiaVerified email at virginia.edu
